Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study of TG01 in combination with gemcitabine and capecitabine in pancreas cancer

Trial Profile

A phase II study of TG01 in combination with gemcitabine and capecitabine in pancreas cancer

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TG 01 Targovax (Primary) ; Capecitabine; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2018 New trial record
    • 11 Jun 2018 According to a Targovax media release, data from some independent trials, testing the chemotherapy cocktail Folfirinox in resected pancreas cancer, have demonstrated an improvement in median overall survival of up to 2 years compared to the current standard of care (gemcitabine and capecitabine). So, the company decides, not to initiate this planned study with gemcitabine and capecitabine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top